PID care following Brexit
The Recommendations on PID care following Brexit were launched on March 6 and are a tailor-made case-study based on primary immunodeficiencies. They aim to ensure that patients with PIDs and other rare diseases both in EU and in the UK continue to benefit from the best possible care and that research and collaboration between healthcare professionals and researchers in Europe after Brexit may continue.
The paper calls upon the UK government and EU negotiators to ensure that even though the negotiations prioritise issues of trade, the health of all European citizens is on the agenda of negotiations that seek a positive collaborative future.
Read the recommendations here.